Ally+
Ally+Request the pitch

Pre-seed round

Adherence and wellbeing for people living with HIV.

Spain and Latin America. A health companion, private by design, licensed to pharmaceutical companies.

Request the pitch
You know in seconds if it’s safe.

Nobody drops treatment because they forgot a pill.

They drop it because of stigma, anxiety, contradictory information, travel and interactions nobody explained. The system is there for a few minutes every few months. Ally+ is there the other 364 days.

Nearly 4 in 10

people on treatment do not reach 90% adherence.

OHTN Rapid Response (2021), citing a meta-analysis of 84 studies.

One third

the odds of virologic failure with optimal versus suboptimal adherence (OR 0.34).

Bezabhe et al., Medicine (2016). Meta-analysis of 43 studies, 27,905 people.

Five moments where Ally+ shows up.

How it works →

Three revenue streams. One primary, clear.

Main engine

B2B2C - licences to pharma

The pharmaceutical company offers Ally+ to its patients: better adherence, better persistence, clinical and commercial value.

Secondary

Freemium

Subscription for advanced features.

Future

Real-world evidence

Aggregated, anonymised data with every GDPR safeguard.

The road ahead.

  1. 2026

    Working MVP: real push reminders, interactions, emotional diary, travel and GDPR architecture.

  2. 2027

    First pilot and first contract with a pharmaceutical company or health system.

  3. 2028

    Expansion in Europe.

  4. 2029

    Expansion in Latin America.

  5. 2030

    Expansion in Africa.

We are opening conversations.

We share the full pitch, product data and the plan with pharma in a private meeting.

Request the pitch

The team.

We are looking for a CTO and a COO, plus AI and pharma advisors.

Let’s talk.

We’ll send you the pitch and set up a live demo.

Request the pitch

Figures cite their source. We do not publish market estimates without a verifiable method.